Targeting effectual epitopes is essential for therapeutic antibodies to accomplish their desired biological functions. This study developed a competitive dual color fluorescence-activated cell sorting (FACS) to maturate a matrix metalloprotease 14 inhibitory antibody. Epitope-specific screening was achieved by selection on MMP-14 during competition with N-terminal domain of tissue inhibitor of metalloproteinase-2 (TIMP-2) (nTIMP-2), a native inhibitor of MMP-14 binding strongly to its catalytic cleft.
controls into the initial screening procedures (Puri, Streaker, Prabakaran, Zhu, & Dimitrov, 2013; Zhang et al., 2006) .
One excellent example of epitope-specific interaction can be found between proteolytic enzymes and their macromolecular inhibitors (Farady, & Craik, 2010; Laskowski & Kato, 1980; Murphy, 2011) . Most protease inhibitory proteins achieve their functions by directly recognizing the protease active site in a substrate-like competitive manner (Nagase, Visse & Murphy, 2006) . Inspired by this orthosteric inhibition mechanism, we aimed to develop a highthroughput epitope-specific screening method to engineer protease inhibitory antibodies. More specifically, a biomedically important protease, matrix metalloprotease 14 (MMP-14) was chosen as a model target for the development.
MMP-14 is a zinc-dependent endopeptidase associated with tumor growth, metastasis, and angiogenesis (Ager et al., 2015; Remacle et al., 2017; Sela-Passwell et al., 2012; Zarrabi et al., 2011) .
MMP-14 also processes proMMP-2 into active MMP-2, the main contributor to the degradation of the extracellular matrix and facilitation of tumor cell migration (Itoh et al., 2001) . Previous failures of all broad-spectrum MMP small-molecule inhibitors in multiple clinical trials taught us that selectivity is key to the success of any MMP inhibition therapy (Overall & Kleifeld, 2006) . However, the high similarity of protein folding and catalytic chemistry among MMP family members presents a daunting challenge for the generation of highly selective compound inhibitors (Turk, 2006) .
Our studies (Lopez, Nam, Kaihara, Mustafa & Ge, 2017; Nam, Fang, Rodriguez, Lopez, & Ge, 2017; Nam, Rodriguez, Remacle, Strongin, & Ge, 2016) , among others (Appleby et al., 2017; Devy et al., 2009; Ling et al., 2017; Udi et al., 2015) , demonstrated the feasibility that antibody-based inhibitors could exhibit the desired high selectivity.
Particularly, Fab3A2 with 4.8 nM affinity, 9.7 nM potency, and high selectivity toward MMP-14 was isolated from a library containing ultralong CDR H3s (Nam et al., 2016) . However, like many standard mechanism protease inhibitors or inhibitory mAbs (Farady, Sun, Darragh, Miller, & Craik, 2007; Zakharova, Horvath, & Goldenberg, 2009 ), 3A2 can be cleaved by its target, MMP-14, after incubation at low pH for an extended period (Supporting Information Figure S1 ).
For therapeutic development, it is necessary to improve the proteolytic stability of 3A2 while retaining its inhibition potency and selectivity.
Cell surface display coupled with fluorescence-activated cell sorting (FACS) is a powerful method to select antigen-specific antibodies and improve their binding strength and pharmacokinetics (Boder & Witrrup, 2000; Colby et al., 2004; Feldhaus et al., 2003) .
During in vitro affinity maturation, an existing antibody clone is subjected to site-directed or random mutagenesis (e.g. by errorprone polymerase chain reaction [PCR]), and generated libraries are displayed on the cell surface (e.g. yeast display). After incubation with the fluorescently labeled antigen, cells are quantitatively analyzed for the selection of clones with improved affinity. Notably, affinity maturation can result in epitope drift (Ohlin, Owman, Mach, & Borrebaeck, 1996) . For protease-inhibiting antibodies, isolated variants with higher affinities are not necessarily associated with improved inhibition potency. It is possible that through conventional affinity maturation, the epitope can migrate to a region, which interferes less with the catalytic pocket, resulting in reduced inhibition potency. By conjugating MMP-14 and its native inhibitor TIMP-2 with different fluorescent dyes, we have demonstrated that dual color FACS can distinguish inhibitory clones from noninhibitory clones . This study further develops this method to improve the proteolytic stability of 3A2, while avoiding unwanted epitope drift and retaining inhibition potency. We test the feasibility to govern control over the epitope by selection on MMP-14 under competition with nTIMP-2. In principle, only the 3A2 variants competing with TIMP-2 binding to inhibitory epitopes, designated MMP-14 high , and TIMP-2 low , will be selected ( Figure 1) . Furthermore, the in vitro and quantitative nature of FACS means that the incubation conditions and sorting windows can be adjusted in realtime to provide high stringency, especially by (a) reducing MMP-14 concentration and increasing TIMP-2 concentration and (b) extending incubation time, to isolate highly potent inhibitory clones with improved proteolytic resistance.
F I G U R E 1 Scheme of dual color epitope-specific FACS for inhibitory antibodies with improved stability and high potency. cdMMP-14: catalytic domain of matrix metalloprotease 14; FACS: fluorescence-activated cell sorting; MMP-14: matrix metalloprotease 14; nTIMP-2: N-terminal domain of TIMP-2 [Color figure can be viewed at wileyonlinelibrary.com] 2 | MATERIALS AND METHODS
| Library construction
Genes of variable heavy (V H ) and variable light (V L ) domains of antibody 3A2 (Nam et al., 2016) were amplified to assemble 3A2 scFv (V H -SGGSGGGGSGSGS-V L ) by overlapping PCR. Error-prone PCR of 3A2 scFv gene was performed by using Taq DNA polymerase with 120 µM dATP, 100 µM dCTP, 360 µM dGTP, 2.5 mM dTTP, 5 µg/ml bovine serum albumin, 3.28 mM MgCl 2 and 0.5 mM MnCl 2 .
The generated mutagenesis product was cloned into the yeast display plasmid pCTcon2 (Feldhaus et al., 2003) 
| Fluorescent labeling and FACS
The catalytic domain of MMP-14 was fused with superfolder green fluorescent protein (GFP) (Pédelacq, Cabantous, Tran, Terwilliger, & Waldo, 2006) , expressed in the periplasm of E. coli, and purified with Ni-NTA agarose (Qiagen, Valencia, CA). Enzymatic activity of the resultant cdMMP14-sfGFP was tested with the fluorescence resonance energy transfer (FRET) peptide substrate, M2350 (Bachem, Torrance, CA). The N-terminal domain of TIMP-2 (nTIMP-2) was prepared as previously described (Lee et al., 2017) , and chemically conjugated with Alexa647 
| Antibody production and stability test
Antibody display plasmids were extracted from isolated yeast clones using a Zymoprep plasmid kit (Zymo, Irvine, CA) and transformed into E.
coli for DNA amplification and sequencing. Isolated scFv genes were then cloned into the periplasmic expression vector, pMopac16 (Hayhurst et. al., 2003) for scFv production. For in vitro stability tests, 
| Antibody characterizations
Binding kinetics of produced scFvs towards cdMMP-14 were analyzed fluorescence was monitored with excitation and emission wavelengths at 325 and 392 nm using a Synergy2 microplate reader equipped with Gen5 software (BioTek, Winooski, VT). Inhibition IC 50 was determined by the change in V max at different concentrations of scFv, and potency K I was calculated using the equation: K I = IC 50 /(S/K m + 1) (Brandt, Laux & Yates, 1987) . Lineweaver-Burk plots were established to determine the type of inhibition. Similarly, purified scFvs were tested against cdMMP-9 and cdMMP-14 single point mutants (Nam et al., 2016) Figure S1 ). To improve proteolytic stability, scFv 3A2 wt gene was subjected to error-prone PCR, a well-documented and effective random mutagenesis method for antibody engineering (Daugherty, Chen, Iverson, & Georgiou, 2000; Gram et al., 1992) . The generated error-prone product was cloned to the yeast surface display vector carrying an A- Figure S2 ).
| Epitope-specific FACS design and results
Crystal structure of cdMMP-14 complexed with its native inhibitor nTIMP-2 reveals that the reactive cleft of MMP-14 is directly occupied with a loop conformation of nTIMP-2, formed by its Nterminal residues (Cys1-Val4) and a surface loop (Ala68-Cys72) through a disulfide-bridge between Cys1 and Cys72 (FernandezCatalan et al., 1998) . Possession of such a substrate-like inhibition mechanism implies that an epitope-specific selection can be achieved 
| Monoclonal screening and identifying affinity improved mutants
Thirty scFv clones randomly picked from R3 were analyzed by monoclonal FACS. Results indicated that the majority (23/30) of isolated mutants had a significantly higher Q4 proportion than 3A2 wt.
From this pool of candidates, DNA sequencing the top 10 clones with the highest Q4 (%) values identified five unique clones B1, B3 (six repeats), T1, T3, and T4, with four to seven mutations each scattered throughout their scFv genes in both framework regions and CDRs (Table 1 ). Monoclonal FACS confirmed that Q4 proportions of these mutants were 12%, 15%, 24%, 23% and 30%, respectively, higher than that of 3A2 wt at 10% (Supporting Information Figure S3 ). Notably, considerable portions of sampled cells (7-15%) were located at the Q2 quadrant (double positive on both cdMMP14-sfGFP and nTIMP2-Alexa647). FACS analysis of cells after single-labeled with 500 nM nTIMP2-Alexa647 revealed the relatively high backgrounds of nonspecific binding of nTIMP2-Alexa647 to yeast cells (Supporting Information Figure S2 ), explaining the disparity from conceptual populations located at the Q2 quadrant (Figure 1 ).
The isolated scFv mutant genes were cloned downstream of a Plac promoter and a pelB leader peptide for periplasmic expression in E. coli (Hayhurst et al., 2003) . Binding kinetics of purified 3A2 mutants on cdMMP-14 were measured by biolayer interferometry, and results indicated that B1, B3, and T1 exhibited single-digit nanomolar affinities at 4.9, 6.3, and 2.5 nM, respectively, significantly stronger than that of 3A2 wt at 25 nM. These improvements were mainly contributed by slower dissociation rates (Table 2) were weaker than that of 3A2 wt, which were merely caused by their lower association rates k on s. In fact, k off s of T1 and T3 were improved compared to that of 3A2 wt. Collectively, these results suggested that random mutagenesis followed by dual color epitope-specific FACS generated 3A2 variants with improved affinities especially on disassociation rates k off s, a phenomenon also found by other affinity maturation studies (Rajpal et al., 2005; Yang et al., 1995) .
| Isolated 3A2 mutants were MMP-14 inhibitors with high selectivity and improved stability
Inhibition assays using a FRET peptide substrate indicated that each of the five isolated 3A2 mutants inhibited cdMMP-14 activity, yet with various potencies ranging from 41 nM to 1.3 µM (Table 2) . Particularly, B3 and T1 showed their potencies to be <100 nM, marginally weaker than that of 3A2 wt (Figure 3a) . To demonstrate the selectivity of isolated variants, 1 µM scFvs were incubated with either 10 nM cdMMP-14 or 10 nM highly homologous cdMMP-9 for FRET inhibition assays. Under these conditions, B1, B3, and T1 completely (96-98%) inhibited cdMMP-14 (Figure 3b ), while T4 displayed incomplete inhibition (34%) on cdMMP-14 due to its low potency (Figure 3a ), but none showed cross-reactivity on cdMMP-9 (0% inhibition). However, T3
gave incomplete inhibition on both cdMMP-14 (70%) and cdMMP-9 (30%). Therefore, except for T3, other isolated 3A2 mutants exhibited excellent selectivity, similar to 3A2 wt (96% on cdMMP-14 and 0% on cdMMP-9). During the in vitro stability tests, 1 µM purified scFvs were incubated with 1 µM cdMMP-14 at pH 7.5 37°C, and samples collected at 1-10 hr were densitometrically analyzed for quantification of intact scFvs. As the degradation progress of B3 was shown in Supporting Information Figure S4a , the relative quantities of remaining scFv over time were plotted to determine that the half-life of B3 scFv as 7.5 hr Note. Standard deviations were calculated from three independent measurements. LOPEZ ET AL.
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(Supporting Information Figure S4b) . Similarly, the half lives of other isolated 3A2 scFv variants were measured to be 6.2-11.0 hr ( Figure 3c ; Table 2 ), significantly longer than 3A2 wt scFv at 1.0 hr (Supporting Information Figure S1 ). This dramatic improvement in stability was likely achieved by the extended incubation with cdMMP-14 before and during FACS experiments, while the inhibition function and selectivity were well retained by controlling the epitope specificity via competition with nTIMP-2 during dual color sorting. Figure S5 ), suggesting that all isolated mutants had a competitive mode of inhibition. To further investigate whether these competitive inhibitions were governed by orthosteric or allosteric regulations, we performed alanine scanning on three phenylalanine residues F198, F204, and F260 of cdMMP-14 (Figure 5a ). They were chosen because these surface-exposed residues are located around the catalytic cleft (yellow in Figure 5a ) and among the binding epitope of nTIMP-2 (red in Figure 5a ). cdMMP-14 site-directed mutants F198A, F204A, and F260A were produced and incubated with scFvs before their kinetic assays, to check whether these alanine mutations affected the inhibition function of scFvs (Figure 5b ). With cdMMP-14 mutant F260A, scFvs T1, T4, and 3A2 wt had no inhibition capability, suggesting that these scFvs interacted with cdMMP-14 wt strongly through F260. However, this was not true of scFvs B1, B3, and T3. In contrast, B1, B3, and T3 showed reduced inhibition of cdMMP-14 mutant F204A to varying degrees, implying that their epitopes at least partially shifted from F260 to F204. Interestingly, clone T1 also showed a reduction in inhibition with the F204A mutant, suggesting that it bound to both F204 and F260, which are located at the two sides of the catalytic center. With F198A, none of the tested scFv clones showed reduced inhibition, indicating tested scFvs did not directly interact with F198. Collectively, the enzyme kinetics and alanine scanning results suggested that isolated 3A2 variants were competitive inhibitors directly binding in the vicinity of the MMP-14 catalytic cleft. Therefore, dual color sorting with nTIMP-2 as the competitor is an effective method to control epitope specificity of isolated antibodies.
3.6 | IgG B3 showed nanomolar affinity and potency with expected in vivo half-life in mice dropped to 73.1%, 24.2%, 3.6%, 2%, and 0.05% at Days 3, 6, 9, 12, and 15, respectively (Figure 6c ), giving a half-life of~4.6 days, similar to that of serum immunoglobulins in adult mice (Vieira & Rajewsky, 1988) .
| DISCUSSION

Studies of therapeutic mAbs have shown that targeting effectual
epitopes is absolutely required to produce the desired biological effect. For instance, HIV broadly neutralizing mAb b12 achieves its protective efficacy by recognizing a hidden but highly conserved epitope that overlaps with the CD4 binding site on gp120 (Zhou et al., 2007) . In the case of trastuzumab, it binds to domain IV of the HER2 extracellular segment, which blocks its signal transduction and inhibits cancer cell growth. However, some HER2-specific mAbs targeting different epitopes exhibit opposite effects by stimulating tumor growth (Yip et al., 2001 ). To achieve epitopespecific selection, competitive phage panning and FACS have been developed (Puri et al., 2013; Zhang et al., 2006) . In an effort to isolate MMP-14 inhibitory mAbs, the use of nTIMP-2, a native inhibitor of MMP-14 as a competitive eluent led to the successful discovery of a panel of inhibitory clones (Devy et al., 2009; Nam et al., 2016) . The current study developed a dual color FACS to perform selection on cdMMP-14 under competition with nTIMP-2 to govern needed control over epitope. Furthermore, the quantitative nature of FACS allowed the conditions and sorting windows to be readily adjusted, for example, by reducing cdMMP-14 concentration and increasing nTIMP-2 concentration (Figure 2 that provided the desired stringency to generate highly potent inhibitory clones. Using these approaches, we isolated 3A2 variants that exhibited affinity improvement while maintaining high inhibition potency and high selectivity (Table 2 and Figure 3 ).
Our results indicate that even though epitope drift indeed happened for some of the isolated clones (e.g. F260 to F204 for scFvs B1 and B3; Figure 5b ), dual color competitive FACS kept the effectual inhibitory functions.
Standard mechanism protease inhibitors bind their targets in a substrate-like manner by inserting a reactive loop into the catalytic cleft (Farady & Craik, 2010; Laskowski & Kato, 1980) .
Upon binding, the scissile bond of the inhibitor is slowly hydrolyzed by the targeted protease (Farady et al., 2007; Zakharova et al., 2009) . Improving proteolytic resistance of a protease inhibitor essentially biases toward inhibition rather than substrate behavior. The challenge of such a task was well demonstrated by attempts to generate pepsin/chymotrypsinresistant hirudin, a thrombin-specific inhibitor (Wirsching, Keller, Hildmann, Riester, & Schwienhorst, 2003) . Cohen et al. (2016) developed an elegant yeast display and multimodal library screening approach, and successfully engineered Kunitz protease inhibitor domain with enhanced proteolytic stability and improved inhibition properties toward mesotrypsin. In the current study, we used prolonged cdMMP-14 incubation and epitope-specific FACS and isolated proteolytically resistant inhibitory antibodies with high potency and selection. Notably, the isolated beneficial variants had mutations located throughout the entire scFv gene (Table 1 ). This suggests that while binding specificity and affinity are largely given by CDRs, the proteolytic stability is strongly influenced by residues within the framework regions, in agreement with other studies (Salameh et al., 2010) .
Isolated mutant B1, B3, and T1 scFvs displayed higher binding affinity than 3A2 wt. However, only B3 exhibited similar inhibition potency compared to 3A2 (Table 2) . Ideally, inhibitory mAbs should exhibit both high binding affinity and high inhibition potency at similar strength, which indicates that the binding epitopes effectively contribute to inhibition. If affinity strength (K D ) is much higher than that of potency (K I ), for example, B1 and T1, it is likely caused by a less effective epitope that has little interference for inhibition. Although B3 scFv showed 4-fold improvement on affinity, when converted to IgG, B3 exhibited a K D of 5.0 nM and a K I of 6.5 nM, which were not improvements compared to 3A2 wt IgG (K D = 3.8 nM, K I = 3.0 nM). Such compromises introduced by format switch are not uncommon for antibody affinity maturation practices. Recent development of Fab yeast display holds great promise for more effective affinity maturation (Wang et al., 2018) .
Protein-protein interactions (PPI) are essential for a wide variety of biological functions (Keskin, Tuncbag, & Gursoy, 2016) , and for any PPI, epitope specificity is critical. Targeting desired epitopes and avoiding ineffectual or adverse epitopes is also critical for the successful development of biosimilars or biosuperiors. In addition to protease inhibitory antibodies, the competitive FACS described here can be applied for discovery and engineering of biosimilars, and in general for other circumstances where epitope-specific modulation is needed.
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